squamous cell carcinoma

News

Regeneron's Libtayo stakes out new territory in skin cancer

Regeneron's Libtayo has become the first checkpoint inhibitor to be cleared by the FDA as an adjuvant treatment for cutaneous squamous cell carcinoma.

News

ASCO 25: Regeneron hails Libtayo's adjuvant data in CSCC

Regeneron's PD-1 inhibitor Libtayo hits the mark where MSD's Keytruda missed in a form of non-melanoma skin cancer.

News

FDA says no to Checkpoint’s skin cancer drug cosibelimab

Checkpoint Therapeutics’ late entry into the PD-1/PD-L1 inhibitor category, cosibelimab, just got knocked back even further after it was turned down by the FDA as a treatm

Regeneron's Libtayo stakes out new territory in skin cancer

ASCO 25: Regeneron hails Libtayo's adjuvant data in CSCC

FDA says no to Checkpoint’s skin cancer drug cosibelimab

ASCO 2026: Chinese firms take a front seat in oncology, with...

Discover a new era of healthcare panel engagement: Grounded ...

squamous cell carcinoma

Editor's Picks